Gosset Ownership
Private
Employees
~10
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Nalo Therapeutics General Information
NX-019, a brain-penetrant EGFR inhibitor, is currently in a First-in-Human clinical study in NSCLC in the US and Asia. NX-201, targeting Myc degradation, is in preclinical development.
Contact Information
Primary Industry
Biotech
Corporate Office
San Francisco, California
United States
United States
Drug Pipeline
NX-019
Phase 1Key Partnerships
Nalo Therapeutics Funding
No funding data available
To view Nalo Therapeutics's complete valuation and funding history, request access »